Comparative Pharmacology
Head-to-head clinical analysis: E E S versus E E S 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S versus E E S 400.
E.E.S. vs E.E.S. 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (E.E.S.) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis. It also exhibits prokinetic effects on the gastrointestinal tract via motilin receptor agonism.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. At high concentrations, it may also inhibit RNA synthesis.
250-500 mg every 6 hours orally or 15-20 mg/kg/day IV divided every 6 hours.
Erythromycin ethylsuccinate 400 mg orally every 6 hours. For severe infections, up to 4 g/day in divided doses.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in patients with hepatic impairment; may be shorter in children.
1.5-2.0 hours in adults with normal renal function; may be prolonged in hepatic impairment (up to 5-6 hours) but not significantly changed in renal disease.
Primarily hepatic (biliary) excretion of unchanged drug and active metabolites; approximately 15% of an oral dose is excreted unchanged in urine. The remainder is eliminated via feces as unchanged drug and metabolites.
Primarily hepatic (biliary) excretion of unchanged drug and metabolites; approximately 2-5% renal excretion of unchanged drug; 5-15% fecal elimination.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic